Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CardiaTec Biosciences leverages proprietary large-scale human cardiac tissue multiomics data—integrating genomics, epigenomics, transcriptomics, and proteomics—with advanced AI to decode complex cardiovascular biology. The company’s approach aims to identify novel therapeutic targets for first-in-class drugs addressing major unmet needs in cardiovascular disease. As of mid–2025, the company has built a unique dataset through partnerships with over 65 hospitals but has not yet announced clinical-stage assets or results.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CardiaTec Biosciences.